SAB Biotherapeutics Inc (SABS) — Cash Flow Quality Index
SAB Biotherapeutics Inc (SABS) has a Cash Flow Quality Index of -2.44x as of September 2025. Operating cash flow of $-13.05 Million is below net income of $5.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how efficiently does SAB Biotherapeutics Inc generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
SAB Biotherapeutics Inc Cash Flow Quality Index (2020–2025)
Historical Cash Flow Quality Index for SAB Biotherapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check SABS cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for SAB Biotherapeutics Inc (2020–2025)
Year-by-year earnings quality comparison for SAB Biotherapeutics Inc. For live market cap and the full company financial profile, see market cap of SAB Biotherapeutics Inc.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -3.37x | $-44.78 Million | $13.27 Million | ▼ -778.3% |
| 2020 | 0.50x | $10.00 Million | $20.12 Million | — |